Literature DB >> 2466368

An in vitro system for screening anti-hepatitis B virus drugs.

K Ueda1, T Tsurimoto, T Nagahata, O Chisaka, K Matsubara.   

Abstract

A human hepatoblastoma cell line (HB 611) that continuously synthesizes hepatitis B viral (HBV) DNA was grown in the presence of various inhibitors of DNA synthesis, and the DNA from the cells was analyzed by the Southern blotting method to examine selective inhibition of the viral DNA synthesis. Among those that showed selective inhibition, and interferons alpha and beta, acyclovir, and dideoxy cytidine were effective. This system should be useful for screening new antiviral agents against HBV.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2466368     DOI： 10.1016/0042-6822(89)90057-3

Source DB:  PubMed          Journal:  Virology        ISSN： 0042-6822            Impact factor:   3.616


  22 in total

1.  Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA.

Authors:  W E Delaney; T G Miller; H C Isom
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Lactosamination of liposomes and hepatotropic targeting research.

Authors:  Yong-Peng Chen; Lian Zhang; Qiao-Sheng Lu; Xiao-Rong Feng; Kang-Xian Luo
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

3.  Comparative inhibition of hepatitis B virus DNA polymerase and cellular DNA polymerases by triphosphates of sugar-modified 5-methyldeoxycytidines and of other nucleoside analogs.

Authors:  E Matthes; K Reimer; M von Janta-Lipinski; H Meisel; C Lehmann
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

4.  Biosynthesis of Oxetanocin-A Includes a B12-Dependent Radical SAM Enzyme That Can Catalyze both Oxidative Ring Contraction and the Demethylation of SAM.

Authors:  Aoshu Zhong; Yu-Hsuan Lee; Yung-Nan Liu; Hung-Wen Liu
Journal:  Biochemistry       Date:  2021-02-09       Impact factor: 3.162

5.  Inhibition of the replication of hepatitis B virus by the carbocyclic analogue of 2'-deoxyguanosine.

Authors:  P M Price; R Banerjee; G Acs
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

6.  Inhibition of duck hepatitis B virus replication by 2',3'-dideoxy-3'-fluoroguanosine in vitro and in vivo.

Authors:  P Hafkemeyer; A Keppler-Hafkemeyer; M A al Haya; M von Janta-Lipinski; E Matthes; C Lehmann; W B Offensperger; S Offensperger; W Gerok; H E Blum
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 7.  Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Authors:  P C Rensen; R L de Vrueh; T J van Berkel
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

8.  Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues.

Authors:  S L Doong; C H Tsai; R F Schinazi; D C Liotta; Y C Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

9.  (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes.

Authors:  L D Condreay; J P Condreay; R W Jansen; M T Paff; D R Averett
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

10.  2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo.

Authors:  F Zoulim; E Dannaoui; C Borel; O Hantz; T S Lin; S H Liu; C Trépo; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.